Selected article for: "activation potential and acute infection"
Author: Barkoff, Courtney M.; Mousa, Shaker A.
Title: Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
  • Cord-id: f6t0fkez
  • Document date: 2020_12_24
    • ID: f6t0fkez
    Snippet: Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the pot
    Document: Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the potential impact of complement activation in COVID-19 and possible treatments targeting the complement system.

    Search related documents:
    Co phrase search for related documents
    • access program and low mortality: 1, 2
    • activation site and acute lung injury: 1
    • acute lung injury and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute lung injury and lmwh weight heparin: 1
    • acute lung injury and low molecular lmwh weight heparin: 1
    • acute lung injury and low mortality: 1, 2, 3, 4, 5
    • acute lung injury and lung biopsy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • administration avoid and liver injury: 1
    • administration avoid and loading dose: 1
    • liver injury and loading dose: 1, 2
    • liver injury and low mortality: 1
    • lmwh weight heparin and loading dose: 1
    • lmwh weight heparin and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh weight heparin and low mortality: 1, 2, 3, 4
    • loading dose and low molecular lmwh weight heparin: 1
    • loading dose and low mortality: 1
    • long term care facility and low mortality: 1, 2